Renal Denervation for the Treatment of Hypertension
Published: August 05, 2024
- Radiofrequency and ultrasound renal nerve denervation (RDN) are approved by the US Food and Drug Administration for the adjunctive treatment of hypertension (HTN) in patients for whom lifestyle and antihypertensive medications do not adequately control blood pressure (BP).
- RDN has been proven effective in patients with mild, moderate, and resistant hypertension, with a BP-lowering efficacy of RDN comparable to that of an effective antihypertensive drug.
- RDN therapy has a favorable safety profile with a very low incidence of major adverse events. Medium to longer-term safety data show no evidence of associated kidney dysfunction or new or worsening renal artery stenosis, but the continued collection of safety data is important.
Supporting Materials
- Commentary: Renal Denervation for Lowering Blood Pressure: Comments on the AHA Scientific Statement by John M. Flack, MD, MPH, Sergio Rabinovich Endowed Chair of Internal Medicine, Professor and Chair, Departments of Medicine and Population Science and Public Policy
- Top Things to Know: Renal Denervation for the Treatment of Hypertension
Recommended Reading
- Hypertension in Patients Treated With In-Center Maintenance Hemodialysis
- Management of Hypertension in Patients With Ventricular Assist Devices
- Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy
- Weight-Loss Strategies for Prevention and Treatment of Hypertension
- Management of Stage 1 Hypertension in Adults With a Low 10-Year Risk for Cardiovascular Disease
- Animal Models of Hypertension
- Resistant Hypertension: Detection, Evaluation, and Management
- Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure
- Impact of Hypertension on Cognitive Function
- 2019 CVD Primary Prevention Guideline
- 2017 Hypertension Clinical Guidelines